We explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.
Investors 2
| Date | Name | Website |
| 26.10.2023 | MPM Capita... | mpmcapital... |
| - | MPM BioImp... | mpmbioimpa... |
Mentions in press and media 3
| Date | Title | Description |
| 13.09.2023 | Arialys Therapeutics Closes $58M Seed Financing | Arialys Therapeutics, a La Jolla, CA-based biotechnology company advancing therapeutics for autoimmune neuropsychiatry, raised $58M in Seed funding. The round saw participation from Avalon BioVentures, Catalys Pacific, and MPM BioImpact, al... |
| 12.09.2023 | Arialys Therapeutics completes a $58M funding round to advance new precision medicines and expand the treatment possibilities for neuropsychiatric diseases driven by autoimmunity | - |
| - | Arialys Therapeutics | “We explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.” |